F 92502 CN
Latest Information Update: 26 Mar 1998
At a glance
- Originator FAES Farma
- Class Anxiolytics
- Mechanism of Action Serotonin 1A receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 26 Mar 1998 Discontinued-Preclinical for Anxiety disorders in Spain (PO)
- 15 May 1995 Preclinical development for Anxiety disorders in Spain (PO)